314 related articles for article (PubMed ID: 24091072)
1. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
[TBL] [Abstract][Full Text] [Related]
2. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
Mauseth SA; Skurtveit S; Spigset O
Acta Obstet Gynecol Scand; 2013 Oct; 92(10):1208-15. PubMed ID: 23763552
[TBL] [Abstract][Full Text] [Related]
3. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
[TBL] [Abstract][Full Text] [Related]
4. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
Sussman D; Yehoshua A; Kowalski J; Lee W; Kish J; Chaudhari S; Murray B
Int J Clin Pract; 2017 Mar; 71(3-4):. PubMed ID: 28371019
[TBL] [Abstract][Full Text] [Related]
5. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
6. Anticholinergic therapy: do the patients take the pills prescribed?
Jundt K; Schreyer K; Friese K; Peschers U
Arch Gynecol Obstet; 2011 Sep; 284(3):663-6. PubMed ID: 21046135
[TBL] [Abstract][Full Text] [Related]
7. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
[TBL] [Abstract][Full Text] [Related]
9. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
Krhut J; Gärtner M; Petzel M; Sykora R; Nemec D; Tvrdik J; Skoupa J
Scand J Urol; 2014 Feb; 48(1):79-83. PubMed ID: 23870042
[TBL] [Abstract][Full Text] [Related]
10. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
11. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Lua LL; Pathak P; Dandolu V
Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
[TBL] [Abstract][Full Text] [Related]
12. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
14. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.
Sexton CC; Notte SM; Maroulis C; Dmochowski RR; Cardozo L; Subramanian D; Coyne KS
Int J Clin Pract; 2011 May; 65(5):567-85. PubMed ID: 21489081
[TBL] [Abstract][Full Text] [Related]
15. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
16. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
17. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
18. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
19. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting.
Asche CV; Kim J; Kulkarni AS; Chakravarti P; Andersson KE
BJU Int; 2012 Feb; 109(4):572-80. PubMed ID: 21777361
[TBL] [Abstract][Full Text] [Related]
20. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.
Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J
Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
